
# CUNUFL

# Managing Director's address

and the second second

# **Annual General Meeting**

31 October 2023



# Forward-looking statement

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE<sup>®</sup> (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA<sup>®</sup> or NEURACTHEL<sup>®</sup>; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE<sup>®</sup>, CYACÊLLE, PRÉNUMBRA<sup>®</sup> or NEURACTHEL<sup>®</sup> which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2023 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

# Catalysts




## Timelines

	Next 12 months
SCENESSE®	use in adolescents – EMA guidance regulatory filing Canada
Vitiligo	CUV105, n=200 – complete recruitment CUV107, n=200
XP – DNA Repair	CUV151-156 readouts CUV154-158 study start
VP	CUV040 – study complete
CNS disorders	CUV803 – readouts (PRÉNUMBRA®) new indication – study start
NEURACTHEL®	manufacturing progress
PhotoCosmetics	website launch; e-commerce CYACÊLLE global launch events
Finances	earnings growth

# Technology



### The technology – melanocortins



COMPANY	YEAR*	RECEPTOR/S	STATUS	
Merck	1999	MC4R	Abandoned	
Basilea	2003	MC4R	Abandoned	
Abbvie	2008	MC1R, MC3R, MC4R, MC5R	Abandoned	
Novo Nordisk	2014	MC4R	Abandoned	
Zengen	2007	MC1R	Abandoned	
Aequus Bio.	2016	MC3R, MC4R	Research	
U. Cincinnati (Abdel Malek)	2006	MC1R	Research	
MC1R Ventures	2022	MC1R	Undisclosed	
Crinetics Pharm.	2019	MC2R	Phase II	
Santhera	2009	MC4R	Phase II	
Synact	2015	MC1R, MC4R	Phase II	
Mallinckrodt	1952	MC1R-MC5R	Chapter 11, ACTH	
IPSEN	2007	MC4R	Licensed to Rhythm	
Amphastar	1952	MC2R	Approved (sNDA): ACTH	
ANI Pharma	1952	MC2R	Approved (sNDA): ACTH	
Palatin Technology	1986	MC1R	Approved: HSDD	
Rhythm Pharma	2008	MC4R	Approved: obesity/BBS	
CLINUVEL	1987	MC1R, MC3R, MC4R	Approved: afamelanotide In dev: ACTH, small molecule	

BBS: Bardet-Biedl syndrome | HSDD: hypoactive sexual desire disorder | ACTH: adrenocorticotropic hormone | \* Year of initial development

# **Clinical programs**




# **Pharmaceutical pipeline**


	Preclinical Phase I	Phase II	Phase III	Commercial		
	SCENESSE® (afamelanotide 16 mg) in adult EPP (EEA, UK, CH, USA, ISL, CAN, AUS)					
	SCENESSE® (afamelanotide 16 mg) in adolescent EPP					
z	SCENESSE® (afamelanotide 16 mg) in adolescent and adult vitiligo					
SKIN	SCENESSE® (afamelanotide 16 mg) in adolescent and adult XP					
	SCENESSE® (afamelanotide 16 mg) in variegate porphyria					
	CUV9900 transdermal					
	PRÉNUMBRA® in arterial ischaemic stroke					
Z	PRÉNUMBRA® to be disclosed					
BRAIN	NEURACTHEL <sup>®</sup> instant – IS, MS					
	<b>NEURACTHEL®</b> modified release – CNS					

XP; xeroderma pigmentosum | IS; infantile spasms | MS; multiple sclerosis | CNS; central nervous system.

## XP trials – clinical timelines



# Evaluating XP – DNA Repair – clinical endpoints



		CUV156	CUV151
DNA repair markers	<ul> <li>Photoproducts (CPDs)</li> <li>γ-H2AX</li> <li>P53</li> </ul>	- reduction - increase - variable, increase	- reduction at 15 mins (p=0.0039) - pending - pending
Quality of life	Validated questionnaires	pending	
Safety	Treatment-emergent adverse events Clinical & laboratory evaluations	safety profile maintained	
Erythema response Severity Melanin density	Minimal Erythemal Dose (MED) Patient & physician assessments Spectrophotometry	- variable - pending - increase	- reduction (p=0.018) - increase (p<0.05)

Total addressable market: <US\$100m

Europe | USA | Africa | Middle East | S&C America ~1,300 XP patients worldwide

# **Cutaneous porphyrias**



#### Erythropoietic protoporphyria


- Expansion for adolescent patients
- Single dose study CUV052
- Expansion population ~21%



#### Variegate porphyria

- CUV040 study ongoing
- Regulatory assessment SCENESSE<sup>®</sup> label

#### **Total addressable market: US\$300m**



# **Arterial Ischaemic Stroke**

#### **Targeted product position**


A hormonal treatment to assist hypoxic brain

**Study CUV801** (n = 6) proof of concept – afamelanotide

- open-label, up to 4 doses: days 0, 1, 7, 8; evaluation at day 42
- occlusion higher regions: > M1
- functional recovery in 5 patients; NIHSS  $\geq$  4 (4/6)
- cerebral perfusion improved per MRI-FLAIR (CBF, Tmax)

**Study CUV803** (n = 12) first patient treated March 2023

- moderate & severe patients
- occlusion higher regions: > M2/A2/P2
- higher, more frequent dosing, PRÉNUMBRA®
- safety
- neurological functionality (NIHSS)
- perfusion of penumbra, oligemic zone



Total addressable market: US\$31B Penetration US\$1.98-2.23B - USA + EU + AU

# Vitiligo – global Phase III study (CUV105)

	CLINUVEL CUV105 Phase III	Pfizer pivotal Phase III oral JAK inhibitor*
Study population	N=200, adults and adolescents (≥12 years) highest unmet need: darker skin (Fitzpatrick IV-VI)	
Inclusion	≥0.3% body surface area with facial vitiligo: T-VASI ≥0.3 & F-VASI ≥0.3	
Primary endpoint	rate of repigmentation of total body surface (T-VASI50)	proportion of participants achieving F-VASI75
Secondary endpoint/s	evaluate repigmentation of the face, maintenance of repigmentation	proportion of participants achieving T-VASI50
Randomisation	1:1 to SCENESSE <sup>®</sup> + NB-UVB vs NB-UVB monotherapy	
Treatment duration	20-week treatment phase, six-month follow up	
Sites	expert treatment centres globally	
Status	12-month recruitment (to October 2024)	

"Once on the market, SCENESSE<sup>®</sup> will clinically become the pigment booster"

Vitiligo Expert Panel member


# Vitiligo – path to market



NB-UVB treatment



NB-UVB + afamelanotide



- **Step 1** >15,200 doses afamelanotide administered<sup>2</sup>
  - Safety profile accepted

#### Step 2 NB-UVB combination

- program planning resulted in savings \$75 145M
- **Step 3 2022 FDA precedent for NB-UVB as combination therapy**
- **Step 4 2022 Insurers providing reimbursement codes**
- **Step 5 Project finance clinical trials A\$77m**
- Step 6 2023 Vitiligo Expert Panel

Step 7 Train & accredit 120 US centres pre-marketing


Total addressable market NAM: US\$490-570m


- Penetration 9% TAM, yr 1-2

<sup>1</sup> Regulatory timelines are dictating timings and progress of filings | <sup>2</sup> All indications | Clinical images courtesy of CUV102 investigators

# **Targeted Technology Translation**

# PhotoCosmetics











#### CYACÊLLE Polychromatic screen

### **PhotoCosmetics**

#### **Identity & visibility**

- architecture
- launch events 2024-25-26

#### Advocacy

- •CUVA (60)
- •CUVIP (10)
- social media

#### **Digital Campaigns**

- •multi-channel
- new digital platform
- cost of customer acquisition
- click through rate (target 3.2%)
- conversion rate (1.8-2.3%)

#### Distribution

- medical
- e-commerce
- high-end retail

**Total addressable market (sunless tanning)** US\$6.2B Penetration yr 1-5: 1% = US\$60M






Radiant

# **Investor Relations & Finance**





# **Registry 2023**


#### **CLINUVEL Shareholders by Type**

% of Issued Capital, September 2023

# Australia and New Zealand Institutions

September 2023

- 30 total ANZ institutions
- 14.2% of issued capital



## Finance




Code	Company	Mkt Cap (A\$m)	FY24e EV/EBITDA	FY24e P/E
AUS Establish	ned Med Tech Companies*			
ASX:CSL	CSL Limited	\$113,080.6	16.4x	24.2x
ASX:RMD	ResMed Inc.	\$31,170.6	14.1x	18.8x
ASX:COH	Cochlear Limited	\$15,887.4	27.1x	43.2x
	Average		<b>19.2</b> x	28.7x
	Median		16.4x	24.2x
Code	Company	Mkt Cap (A\$m)	FY24e EV/EBITDA	FY24e P/E
	Biopharma Companies - Directly ing Novel Drugs in US/EU*			
NASDAQ: AMGN	Amgen Inc.	\$220,196.8	9.2x	13.2x
NASDAQ: BIIB	Biogen Inc.	\$53,452.5	9.3x	14.5x
NASDAQ: REGN	Regeneron Pharmaceuticals, Inc.	\$129,267.3	12.2x	16.3x
NASDAQ: INCY	Incyte Corporation	\$18,529.2	6.9x	11.1x
NASDAQ: JAZZ	Jazz Pharmaceuticals plc	\$12,526.5	6.1x	5.5x
NYSE: ABBV	AbbVie Inc.	\$385,924.0	11.5x	12.6x
NASDAQ: AZN	AstraZeneca PLC	\$300,041.2	11.7x	14.5x
NYSE: BMY	Bristol-Myers Squibb Company	\$163,381.4	7.0x	6.9x
NASDAQ: GILD	Gilead Sciences, Inc.	\$150,250.1	7.8x	10.5x
NYSE: NVS	Novartis AG	\$300,212.6	10.7x	13.4x
NYSE: PFE	Pfizer Inc.	\$267,545.8	8.3x	9.4x
	Average		9.2x	<b>11.6</b> x
	Median		9.2x	<b>12.6</b> x
ASX:CUV	Clinuvel Pharmaceuticals Limited	\$756.5	12.7x	21.2x

# **CLINUVEL in 2026**



### **Total addressable markets**



Catalysts next 12 months

Prudent fiscal management

Australian institutions

Pharma + PhotoCosmetic

Analyst coverage

### Conclusions

16

CAGR 30%, net assets 31%, cash A\$156.8 (FYE '23)

14%

**Pipeline, commercial launches 2024-25-26** 

**Independent reports published** 

>US\$2B

TAM

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Head of Investor Relations Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD https://www.clinuvel.com/investors/contact-us

www.clinuvel.com Level 11, 535 Bourke Street Melbourne - Victoria, Australia, 3000 T +61 3 9660 4900 F +61 3 9660 4909